Spotlight on ACC 2026: Dyslipidaemia Guideline Updates and Emerging Data
-
7m 45s
-
7m 29sPart 4 Lifestyle and Nutrition
-
8m 44sPart 5 Use of Biomarkers
-
5m 28s
-
12m 29sPart 1 | Session 1 Summary of Guideline Updates on Non-Statin Treatments
-
17m 11sPart 1 | Session 2 Emerging Insights on Non-Statin Treatments
Advances in lipid-lowering therapies have expanded the treatment landscape beyond statins, yet a clear gap remains in their routine clinical adoption. Despite strong and growing evidence supporting the use of non-statin agents, many clinicians face challenges integrating these therapies into practice. Bridging this gap requires both a deeper understanding of emerging therapies and practical guidance on how to apply evolving clinical guidelines.
This educational programme is designed to support healthcare professionals in navigating these challenges, providing a focused spotlight on the Dyslipidaemia guideline updates and emerging data presented at ACC 2026. Through a series of expert-led sessions recorded at ACC 2026, participants will gain actionable insights across key areas:
Intensive LDL-C lowering - Dr Steven Nissen (Cleveland Clinic, Cleveland, US) and Dr Christie Ballantyne (Baylor College of Medicine, Houston, US) share strategies to optimise therapy.
Triglyceride management, personalised risk assessment, biomarker integration, and lifestyle interventions – Dr Erin Michos (Johns Hopkins University School of Medicine, Baltimore, US) and Dr Roger Blumenthal (Johns Hopkins University School of Medicine, Baltimore, US) explore practical approaches to comprehensive cardiovascular care.
Each session is tailored to address real-world clinical challenges, translating evidence into practice and supporting clinicians in delivering more effective, individualised care for patients at cardiovascular risk.
Key Learning Objectives
- Summarise the latest recommendations from the joint ACC/AHA dyslipidaemia guideline on LDL-C and triglyceride lowering, risk assessment, biomarker testing and lifestyle management
- Summarise the latest recommendations from the ACC/AHA on the use of non-statin LDL-C lowering agents in high-risk patients and in that intolerant to statin
- Translate new recommendations with those made on previous European guidelines into your daily practice
- Describe how non-statin treatments achieve their clinical benefit
- Recall MACE benefit of LDL-C lowering agents in patients unable or unwilling to take statins
Target Audience
- Cardiovascular Specialists
- Cardiologists
- Internal Medicine
- Lipidologists
- Endocrinologists
More from this programme
Part 1
Intensive LDL-C Lowering: Life Beyond Statins
Dr Nissen and Dr Ballantyne review recent guideline updates on non-statin therapies, focusing on strategies for statin-intolerant patients and post-ACS management. The session highlights how these novel treatments are being integrated into clinical practice. Emerging data from selected posters provides insights into efficacy, safety, and patient outcomes, offering a concise update on evolving approaches to LDL-C reduction beyond traditional statins.
This session is supported by an unrestricted educational grant from Esperion Therapeutics.
Part 2
Personalised Risk Assessment
Dr Michos and Dr Blumenthal review tools like the PREVENT calculator and SCORE2/SCORE2-OP, highlighting how risk modifiers can refine cardiovascular risk prediction for individual patients.
| 1 session | |
| Personalised Risk Assessment | Watch now |
Part 3
Reframing Triglyceride Management
Dr Michos and Dr Blumenthal explore strategies for reducing cardiovascular risk with EPA, the role of fibrates, and emerging approaches for treating familial chylomicronaemia syndrome, which now includes two approved APOC-III inhibitors.
| 1 session | |
| Reframing Triglyceride Management | Watch now |
Part 4
Lifestyle and Nutrition
Dr Michos and Dr Blumenthal summarise current evidence from recent trials and guidelines, emphasising practical strategies for cardiovascular risk reduction through diet and lifestyle interventions.
| 1 session | |
| Lifestyle and Nutrition | Watch now |
Part 5
Use of Biomarkers
Dr Michos and Dr Blumenthal cover testing recommendations, strategies for risk modification, and emerging therapies targeting key cardiovascular biomarkers.
| 1 session | |
| Use of Biomarkers | Watch now |
Part 6
Top Takeaways from the 2026 Dyslipidaemia Guidelines
Dr Navar summarises key recommendations from the 2026 Dyslipidaemia Guidelines that are shaping the future of lipid management.
Faculty Biographies
Erin D Michos
Associate Professor of Medicine and Director of Women's Cardiovascular Health
Dr Erin Michos is an Associate Professor of Medicine in the Division of Cardiology at the Johns Hopkins University School of Medicine, with joint appointment in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. She is the Director of Women’s Cardiovascular Heath and Associate Director of Preventive Cardiology with the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
Dr Michos is an internationally known expert in Preventive Cardiology and Women’s Health and has authored over 350 publications. Her research has focused on cardiovascular disease among women; coronary artery calcium, inflammatory markers, and other novel biomarkers of cardiovascular risk; lipids; and vitamin D and other supplements. She is an Associate Editor for Circulation and the American Journal of Preventive Cardiology.
Following receipt of her medical degree from Northwestern University, Dr. Michos…
Roger S Blumenthal
The Kenneth Jay Pollin Professor of Cardiology, Professor of Medicine
Dr Roger S. Blumenthal is The Kenneth Jay Pollin Professor of Cardiology, Professor of Medicine and the Director of the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease in Baltimore, Maryland, US. Dr Blumenthal graduated with honors from the Landon School in Bethesda and the Johns Hopkins University. He received his medical degree from Cornell Medical College, where he was awarded the Weiss Prize for Excellence in Clinical Medicine.
He did his Internal Medicine and Cardiology fellowship training at The Johns Hopkins University School of Medicine before joining the Hopkins Cardiology faculty. Dr. Blumenthal was the 2018 recipient of the Landon School Anthony Kupka Distinguished Alumnus Award. He was the 2019 recipient of the Society of Cardiovascular Computed Tomography (SCCT) Arthur S. Agatston Cardiovascular Disease Prevention Award.
His principal clinical and research interests involve strategies to improve cardiovascular risk assessment to…
Comments